No, Ureteral Stents Do Not Require Antiplatelet Therapy
Ureteral stents are fundamentally different from coronary stents and do not require antiplatelet therapy. This is a critical distinction that stems from their completely different mechanisms of action, materials, and clinical purposes.
Why the Difference Exists
Coronary Stents vs Ureteral Stents: Fundamentally Different Devices
Coronary stents are metallic scaffolds placed in blood vessels where they are constantly exposed to flowing blood and platelets. They require antiplatelet therapy (aspirin plus clopidogrel) to prevent thrombosis—the formation of blood clots on the stent surface that can cause heart attacks or strokes. The risk of stent thrombosis is highest in the first 12 months after drug-eluting stent placement and 3 months after bare metal stent placement 1.
Ureteral stents, in contrast, are plastic tubes placed in the urinary tract to maintain urine drainage. They are exposed to urine, not blood, and their complications relate to:
- Encrustation (mineral deposits)
- Infection
- Pain and bladder irritation
- Migration or malposition
- Tissue irritation 2, 3, 4
There is no thrombotic risk with ureteral stents because they do not contact the vascular system in a way that would trigger platelet aggregation or clot formation.
Management of Antiplatelet Therapy During Ureteral Stent Placement
For Patients Already on Antiplatelet Therapy
The relevant clinical question is whether patients who are already taking antiplatelet medications for cardiac or cerebrovascular indications need to stop these medications before ureteral stent placement:
Aspirin can be safely continued during ureteral stent placement and ureteroscopic procedures without significantly increased bleeding risk 1. The ICUD/AUA guidelines specifically state that patients on low-dose aspirin for cardiac risk factors can continue this medication perioperatively for urological procedures including ureteroscopy 1.
Dual antiplatelet therapy (aspirin plus clopidogrel) should ideally not be interrupted within:
- 12 months of drug-eluting stent placement
- 3 months of bare metal stent placement
For patients requiring urgent urological procedures within these timeframes, a multidisciplinary approach with cardiology consultation is essential 1.
Common Pitfalls to Avoid
- Do not confuse the two types of stents: The word "stent" applies to both devices, but they serve entirely different purposes in different organ systems
- Do not start antiplatelet therapy for ureteral stents: There is no indication for initiating aspirin or clopidogrel solely because a ureteral stent is placed
- Do not unnecessarily stop cardiac antiplatelet therapy: If a patient is on aspirin for cardiac indications, it can be safely continued during ureteral stent procedures 1
Summary of Key Differences
| Feature | Coronary Stents | Ureteral Stents |
|---|---|---|
| Location | Blood vessels | Urinary tract |
| Material | Metal (usually) | Plastic/polymer [2,4] |
| Exposure | Blood and platelets | Urine |
| Primary risk | Thrombosis | Encrustation, infection, pain [3,4] |
| Antiplatelet need | Yes, mandatory | No, not indicated |
The confusion likely arises from the shared terminology, but the clinical management is entirely different based on the fundamental biology of where these devices are placed and what complications they face.